Using Ezetimibe After Heart Attacks

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial investigates the early use of Ezetimibe, a cholesterol-lowering medication, in patients who have experienced an acute myocardial infarction (heart attack). The study aims to determine if initiating Ezetimibe alongside high-intensity statin therapy can more effectively lower LDL cholesterol levels and reduce the risk of recurrent heart events. Patients will be monitored for their LDL-C levels and overall cardiovascular health following the intervention. The trial focuses on individuals who have not achieved target cholesterol levels with statins alone.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age more than 18 years. Both genders are eligible.
* Acute myocardial infarction (STEMI or NSTEMI) within 48 hours from the onset of symptoms.
* Baseline LDL-C above 125 mg/dl for those who were not on consistent lipid lowering therapy; or above 100 mg/dl for those who were compliant (≥ 90 days) on moderate intensity statin therapy.

Exclusion Criteria:

* Refusal to participate in the study.
* Proved intolerance to statins on previous use.
* Having conditions (or taking medications) that would not allow concomitant safe statins use. \[such as patients receiving Cyclosporine - Gemfibrozil -Pazopanib - Tipranavir - Itraconazole - Ketoconazole\]
* Those who are already compliant on high intensity statins.
* Those who are already on statins plus non-statin agent (ezetimibe-PCSK9i-BAS).
* Known familial dyslipidemia or having TG\>500 mg/dl or LDL-C\>190 mg/dl which are highly suggestive of familial or secondary causes.
* Pregnant or contemplating pregnancy in the following 12 months. \[relevant for females in the child-bearing period\]

Where it's running

• Aswan Heart Centre
  Aswān, Egypt Recruiting

Study contacts

• Principal investigator: Ahmad Samir, MD — Cairo University
• Study coordinator: Ahmad Samir, MD
• Email: ahmad.samir@kasralainy.edu.eg
• Phone: 00201002647275

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Asprosin and miRNA Profiles in Young Women with Metabolic Syndrome

  This study tests whether certain blood biomarkers, including asprosin and six microRNAs, differ between young women with metabolic syndrome and healthy peers.

  Recruiting University of Applied Sciences in Nowy Targ · Nowy Targ, Lesser Poland Voivodeship · NCT07917364

• Evaluating a noninvasive tissue sensor to detect cardiogenic shock earlier in heart patients

  This pilot, noninvasive study tests whether the NIRSense wearable can help detect deterioration in adults with cardiogenic shock risk due to heart attack or heart failure.

  Recruiting NIRSense Inc. · Weston, Florida · NCT07825363

• Home-based cardiovascular health screening for people turning 50, 55, 60, 65, 70 or 75 in Uppsala

  This trial tests whether giving people a home blood pressure monitor, a dried blood spot kit, and a questionnaire can find more cardiovascular risk factors than usual care.

  Recruiting Uppsala University · Uppsala · NCT07614659

• Group visits to help manage high cholesterol

  This project will try group medical visits for adults with dyslipidemia to see if they improve care, lifestyle habits, and access to primary care.

  Recruiting Université de Sherbrooke · Dieppe, New Brunswick · NCT07543718

• Adenosine given before primary PCI to reduce no-reflow in STEMI patients.

  See if giving intracoronary adenosine before primary PCI lowers the chance of slow flow/no-reflow in adults with STEMI.

  Recruiting at 2 sites Phase 4 National Institute of Cardiovascular Diseases, Pakistan · Karachi, Sindh and 1 other locations · NCT07536802

• Fixed-dose pitavastatin/ezetimibe for adults with dyslipidemia and metabolic syndrome

  This will try a fixed-dose pitavastatin/ezetimibe pill in adults with dyslipidemia and metabolic syndrome to see if it lowers LDL cholesterol and is safe over 48 weeks.

  Recruiting JW Pharmaceutical · Daejeon · NCT07523971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.